THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 122 filers reported holding THERAVANCE BIOPHARMA INC in Q4 2022. The put-call ratio across all filers is 0.21 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $600,900 | -84.5% | 58,058 | -83.7% | 0.00% | -81.8% |
| Q1 2023 | $3,872,007 | -64.2% | 356,867 | -62.9% | 0.01% | -67.6% |
| Q4 2022 | $10,802,908 | +63.2% | 962,826 | +47.5% | 0.03% | +54.5% |
| Q3 2022 | $6,620,000 | +363.9% | 652,870 | +337.5% | 0.02% | +450.0% |
| Q1 2022 | $1,427,000 | +268.7% | 149,240 | +325.6% | 0.00% | +300.0% |
| Q4 2021 | $387,000 | -53.7% | 35,066 | -14.4% | 0.00% | -50.0% |
| Q1 2021 | $836,000 | +43.2% | 40,962 | +3.7% | 0.00% | 0.0% |
| Q3 2020 | $584,000 | -83.8% | 39,519 | -77.0% | 0.00% | -88.9% |
| Q2 2020 | $3,611,000 | +606.7% | 172,050 | +998.9% | 0.02% | +1700.0% |
| Q3 2018 | $511,000 | -40.5% | 15,656 | -41.9% | 0.00% | -66.7% |
| Q4 2016 | $859,000 | +123.1% | 26,931 | +153.3% | 0.00% | +200.0% |
| Q3 2016 | $385,000 | -44.8% | 10,632 | -77.3% | 0.00% | -75.0% |
| Q4 2014 | $698,000 | – | 46,775 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Link Fund Solutions Ltd | 5,251,349 | $135,459,000 | 69.86% |
| Chescapmanager LLC | 949,006 | $24,570,000 | 3.61% |
| Baupost Group | 9,309,168 | $241,014,000 | 2.66% |
| Rock Springs Capital Management LP | 655,200 | $16,963,000 | 0.54% |
| Rubric Capital Management LP | 173,400 | $4,489,000 | 0.51% |
| Newtyn Management, LLC | 173,300 | $4,487,000 | 0.41% |
| NJ State Employees Deferred Compensation Plan | 38,142 | $988,000 | 0.17% |
| King Wealth Management Group | 22,500 | $583,000 | 0.15% |
| Virtus ETF Advisers LLC | 29,216 | $756,000 | 0.12% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 452,615 | $11,718,000 | 0.12% |